In the recent years, advances have been made in the field of cancer research. These advancements are a result of the efforts made by various oncologists to develop cancer therapies. Today, different countries are building state of the art laboratories. These facilities have helped in advancing cancer research. In addition, many experienced researchers such as Mikhail Blagosklonny, have dedicated their lives to fighting cancer.
Mikhail Blagosklonny works for Roswell Park Cancer Institute. The professor of oncology pursued his master’s in internal medicine at the renowned Pavlov State Medical University. The medical expert holds a PhD in experimental medicine and cardiology from the St. Petersburg-based institution. View Mikhail’s profile in LinkedIn
The scientist’s research focuses on anti-aging, cancer and oncology. His interest in the field coupled with a sound educational background has seen him work for various academic institutions. He has also been a leader of different health and science-related organizations. Previously, he worked as an associate professor of medicine at the New York Medical College. Mikhail worked for the Valhalla-based medical college between 2002 and 2006. Later, he joined the Ordway Research Institute as a senior scientist where he worked between 2006 and 2009. After leaving the institution, Mikhail joined Roswell Park Cancer Center as a professor of oncology.
Mikhail Blagosklonny played a pivotal role in enhancing Roswell Park’s success. He has accelerated the company’s research in aging and cancer. As a lecturer, he has been able to teach and equip many students with practical knowledge on cancer, aging and oncology.
The professor of oncology advocates for the use of Rapamycin in the treatment of aging. Mikhail is optimistic that this drug can help in treating cancer. He believes that with time, scientists will be able to develop viable cancer therapies. The existing cancer drugs seeks to prolong the lives of cancer patients. He is credited for coming up with the TOR signaling hypothesis in cancer and aging. Mikhail is also the editor-in-chief of a widely-read journal known as Oncotarget. The scientist serves as the associate editor of Cancer Biology & Therapy Journal. He is also a member of Cell Death & Differentiation’s editorial board. In addition, Mikhail is affiliated with PLOS ONE, the International Journal of Cancer and the American Journal of Pathology.